JP2018531929A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531929A5
JP2018531929A5 JP2018515468A JP2018515468A JP2018531929A5 JP 2018531929 A5 JP2018531929 A5 JP 2018531929A5 JP 2018515468 A JP2018515468 A JP 2018515468A JP 2018515468 A JP2018515468 A JP 2018515468A JP 2018531929 A5 JP2018531929 A5 JP 2018531929A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
liver disease
neuronal loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515468A
Other languages
English (en)
Japanese (ja)
Other versions
JP6989495B2 (ja
JP2018531929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053176 external-priority patent/WO2017053613A1/en
Publication of JP2018531929A publication Critical patent/JP2018531929A/ja
Publication of JP2018531929A5 publication Critical patent/JP2018531929A5/ja
Application granted granted Critical
Publication of JP6989495B2 publication Critical patent/JP6989495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515468A 2015-09-25 2016-09-22 L−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる神経細胞喪失の治療および予防 Active JP6989495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US62/233,002 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (3)

Publication Number Publication Date
JP2018531929A JP2018531929A (ja) 2018-11-01
JP2018531929A5 true JP2018531929A5 (https=) 2019-11-07
JP6989495B2 JP6989495B2 (ja) 2022-01-05

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515468A Active JP6989495B2 (ja) 2015-09-25 2016-09-22 L−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる神経細胞喪失の治療および予防

Country Status (7)

Country Link
US (1) US20200206174A1 (https=)
EP (1) EP3352748A4 (https=)
JP (1) JP6989495B2 (https=)
AU (1) AU2016325556B2 (https=)
CA (1) CA2998490A1 (https=)
HK (1) HK1257679A1 (https=)
WO (1) WO2017053613A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
CN108366983A (zh) * 2015-11-13 2018-08-03 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
WO2019226786A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
SG11202111509PA (en) * 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) * 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能

Similar Documents

Publication Publication Date Title
JP2018531929A5 (https=)
JP2018523683A5 (https=)
JP2014505688A5 (https=)
CN105899213A (zh) 氧化胆固醇硫酸酯(ocs)的方法
RU2019110150A (ru) Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции
RU2016127558A (ru) Стероидное соединение для применения в лечении печеночной энцефалопатии
HRP20210294T1 (hr) Postupci liječenja akutnog bubrežnog oštećenja
JP2016535780A5 (https=)
JP2017514911A5 (https=)
JP2008545703A5 (https=)
ES2361915T3 (es) Utilización de la betaína para el tratamiento de la claudicación intermitente.
Liu et al. Urolithin A alleviates early brain injury after subarachnoid hemorrhage by regulating the AMPK/mTOR pathway-mediated autophagy
JP2006524699A5 (https=)
EA201792565A1 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2008520681A5 (https=)
CN107648213A (zh) 恩利卡生在制备治疗缺血/再灌注损伤药物中的应用
ES2965493T3 (es) Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en concreto caracterizadas por una disminución de la plasticidad sináptica
El Gharabawy et al. Histological effects of sofosbuvir on the kidney of male albino rats and the possible protective role of vitamin C
EP4477223A4 (en) A pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt, combined for the prevention or treatment of chronic nephropathy in a patient with elevated blood uric acid levels.
CN101991573A (zh) 去氢钩藤碱及其异构体在制备药物中的用途
JP7699855B2 (ja) シロスタゾールを含む組成物の脳血管疾患の治療薬の調製への応用
JP7778396B2 (ja) シロスタゾールを含む組成物の脳血管疾患への応用
JP2022543598A5 (https=)
CN103800318B (zh) 巴西苏木素在制备用于防治肝肾损伤的药物中的应用
CN104721189B (zh) 朴莫伐明在制备防治缺血性脑血管病药物中的应用